|startresults
nifedipine	theophylline	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
nifedipine	Warfarin	13	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  (See                                       PRECAUTIONS: General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	phenobarbital	13	14	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
nifedipine	cimetidine	13	14	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
nifedipine	PLAVIX	13	11	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  (See                                       PRECAUTIONS: General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	PLAVIX	13	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	PLAVIX	13	14	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
nifedipine	PLAVIX	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
nifedipine	warfarin	13	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  (See                                       PRECAUTIONS: General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	digoxin	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
nifedipine	atenolol	13	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	clopidogrel bisulfate	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
nifedipine	clopidogrel	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
nifedipine	estrogen	13	14	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
theophylline	tamoxifen	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	Warfarin	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	phenobarbital	15	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
theophylline	cimetidine	15	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
theophylline	fluvastatin	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	torsemide	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	PLAVIX	15	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
theophylline	PLAVIX	15	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
theophylline	PLAVIX	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
theophylline	PLAVIX	15	17	true	positive	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	warfarin	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	digoxin	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
theophylline	atenolol	15	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
theophylline	phenytoin	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	clopidogrel bisulfate	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
theophylline	clopidogrel	15	16	true	negative	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
theophylline	clopidogrel	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
theophylline	tolbutamide	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	estrogen	15	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
LMWH	tamoxifen	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	Warfarin	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	fluvastatin	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	torsemide	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	PLAVIX	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	PLAVIX	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	PLAVIX	19	18	false	none	Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	warfarin	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	Heparin	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	phenytoin	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	clopidogrel	19	20	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  There are no data on the concomitant use of oral anticoagulants, non study oral anti-platelet drugs and chronic NSAIDs with clopidogrel.  	
LMWH	tolbutamide	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	heparin	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	insulin	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
LMWH	cholesterol	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
tamoxifen	Warfarin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	fluvastatin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	torsemide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	PLAVIX	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	PLAVIX	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	PLAVIX	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
tamoxifen	PLAVIX	17	18	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  	
tamoxifen	warfarin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	digoxin	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	Heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
tamoxifen	phenytoin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel bisulfate	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel	17	16	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	tolbutamide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
tamoxifen	insulin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
tamoxifen	cholesterol	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Warfarin	fluvastatin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	torsemide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	PLAVIX	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	PLAVIX	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	PLAVIX	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Warfarin	PLAVIX	17	18	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  	
Warfarin	PLAVIX	11	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  NSAIDs and PLAVIX should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
Warfarin	PLAVIX	11	10	false	none	NSAIDs and PLAVIX should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
Warfarin	PLAVIX	11	11	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
Warfarin	PLAVIX	11	13	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  (See                                       PRECAUTIONS: General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Warfarin	warfarin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	warfarin	11	11	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
Warfarin	digoxin	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	naproxen	11	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  NSAIDs and PLAVIX should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
Warfarin	atenolol	11	13	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  (See                                       PRECAUTIONS: General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Warfarin	Heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Warfarin	phenytoin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	clopidogrel bisulfate	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	clopidogrel	17	16	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	clopidogrel	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	tolbutamide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Warfarin	insulin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Warfarin	cholesterol	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
phenobarbital	cimetidine	14	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	PLAVIX	14	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	PLAVIX	14	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	PLAVIX	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
phenobarbital	digoxin	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
phenobarbital	atenolol	14	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	clopidogrel bisulfate	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
phenobarbital	clopidogrel	14	16	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
phenobarbital	clopidogrel	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
phenobarbital	estrogen	14	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	PLAVIX	14	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	PLAVIX	14	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	PLAVIX	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
cimetidine	digoxin	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
cimetidine	atenolol	14	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	clopidogrel bisulfate	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
cimetidine	clopidogrel	14	16	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
cimetidine	clopidogrel	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
cimetidine	estrogen	14	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
fluvastatin	torsemide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	PLAVIX	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	PLAVIX	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	PLAVIX	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
fluvastatin	PLAVIX	17	18	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  	
fluvastatin	warfarin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	digoxin	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	Heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
fluvastatin	phenytoin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	clopidogrel bisulfate	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	clopidogrel	17	16	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	clopidogrel	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	tolbutamide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
fluvastatin	insulin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
fluvastatin	cholesterol	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
torsemide	PLAVIX	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	PLAVIX	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	PLAVIX	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
torsemide	PLAVIX	17	18	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  	
torsemide	warfarin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	digoxin	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	Heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
torsemide	phenytoin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	clopidogrel bisulfate	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	clopidogrel	17	16	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	clopidogrel	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	tolbutamide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
torsemide	insulin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
torsemide	cholesterol	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Aspirin	PLAVIX	3	4	true	negative	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
Aspirin	PLAVIX	3	5	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	PLAVIX	4	4	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
Aspirin	PLAVIX	4	5	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	PLAVIX	4	6	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	PLAVIX	5	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	PLAVIX	5	5	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	PLAVIX	5	6	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	PLAVIX	5	7	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	PLAVIX	6	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	PLAVIX	6	5	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	PLAVIX	6	6	false	none	PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	PLAVIX	6	7	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	PLAVIX	6	8	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
Aspirin	aspirin	3	3	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
Aspirin	aspirin	3	4	true	negative	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
Aspirin	aspirin	3	5	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	4	3	true	negative	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
Aspirin	aspirin	4	4	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
Aspirin	aspirin	4	5	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	4	6	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	aspirin	5	3	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	5	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	5	5	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	5	6	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	aspirin	6	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	aspirin	6	5	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	aspirin	6	6	false	none	PLAVIX and aspirin have been administered together for up to one year.  	
Aspirin	Heparin	5	7	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	Heparin	6	7	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	Heparin	6	8	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
Aspirin	clopidogrel	3	1	true	negative	Drug Interactions                                                 Since clopidogrel is metabolized to its active metabolite by CYP2C19, use of drugs that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel and a reduction in clinical efficacy.  Concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.  Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
Aspirin	clopidogrel	3	3	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
Aspirin	clopidogrel	4	3	true	negative	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
Aspirin	clopidogrel	5	3	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	heparin	5	7	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	heparin	6	7	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	heparin	6	8	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
Aspirin	omeprazole	3	2	true	negative	Concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.  Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
Aspirin	omeprazole	4	2	true	negative	Concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.  Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
PLAVIX	warfarin	9	11	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  NSAIDs and PLAVIX should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
PLAVIX	warfarin	10	11	false	none	NSAIDs and PLAVIX should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
PLAVIX	warfarin	11	11	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
PLAVIX	warfarin	13	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  (See                                       PRECAUTIONS: General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
PLAVIX	warfarin	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	warfarin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	warfarin	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	warfarin	18	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  	
PLAVIX	digoxin	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	digoxin	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	digoxin	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	digoxin	17	15	true	positive	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	naproxen	7	9	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
PLAVIX	naproxen	8	9	true	negative	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
PLAVIX	naproxen	9	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
PLAVIX	naproxen	10	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  NSAIDs and PLAVIX should be coadministered with caution.  	
PLAVIX	naproxen	11	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  NSAIDs and PLAVIX should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
PLAVIX	atenolol	11	13	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  (See                                       PRECAUTIONS: General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
PLAVIX	atenolol	13	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
PLAVIX	atenolol	14	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
PLAVIX	atenolol	15	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	aspirin	4	3	true	negative	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
PLAVIX	aspirin	4	4	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
PLAVIX	aspirin	4	5	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
PLAVIX	aspirin	4	6	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
PLAVIX	aspirin	5	3	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
PLAVIX	aspirin	5	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
PLAVIX	aspirin	5	5	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
PLAVIX	aspirin	5	6	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
PLAVIX	aspirin	6	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
PLAVIX	aspirin	6	5	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  	
PLAVIX	aspirin	6	6	false	none	PLAVIX and aspirin have been administered together for up to one year.  	
PLAVIX	aspirin	7	5	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
PLAVIX	aspirin	7	6	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
PLAVIX	aspirin	8	6	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
PLAVIX	Heparin	5	7	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
PLAVIX	Heparin	6	7	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
PLAVIX	Heparin	6	8	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
PLAVIX	Heparin	7	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
PLAVIX	Heparin	7	8	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
PLAVIX	Heparin	8	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
PLAVIX	Heparin	8	8	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
PLAVIX	Heparin	9	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
PLAVIX	Heparin	9	8	true	negative	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
PLAVIX	Heparin	10	8	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  NSAIDs and PLAVIX should be coadministered with caution.  	
PLAVIX	Heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	Heparin	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	Heparin	18	19	false	none	Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	phenytoin	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	phenytoin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	phenytoin	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	phenytoin	18	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  	
PLAVIX	clopidogrel bisulfate	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	clopidogrel bisulfate	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	clopidogrel bisulfate	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	clopidogrel bisulfate	17	15	true	positive	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	clopidogrel	4	3	true	negative	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
PLAVIX	clopidogrel	5	3	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
PLAVIX	clopidogrel	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	clopidogrel	14	16	true	negative	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
PLAVIX	clopidogrel	14	15	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	clopidogrel	15	16	true	negative	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
PLAVIX	clopidogrel	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	clopidogrel	17	16	true	positive	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	clopidogrel	17	15	true	positive	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	clopidogrel	19	20	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  There are no data on the concomitant use of oral anticoagulants, non study oral anti-platelet drugs and chronic NSAIDs with clopidogrel.  	
PLAVIX	clopidogrel	18	16	true	positive	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  	
PLAVIX	clopidogrel	18	20	false	none	Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  There are no data on the concomitant use of oral anticoagulants, non study oral anti-platelet drugs and chronic NSAIDs with clopidogrel.  	
PLAVIX	tolbutamide	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	tolbutamide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
PLAVIX	tolbutamide	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	tolbutamide	18	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  	
PLAVIX	estrogen	13	14	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
PLAVIX	estrogen	14	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
PLAVIX	estrogen	15	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
PLAVIX	heparin	5	7	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
PLAVIX	heparin	6	7	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
PLAVIX	heparin	6	8	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
PLAVIX	heparin	7	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
PLAVIX	heparin	7	8	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
PLAVIX	heparin	8	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
PLAVIX	heparin	8	8	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
PLAVIX	heparin	9	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
PLAVIX	heparin	9	8	true	negative	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
PLAVIX	heparin	10	8	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  NSAIDs and PLAVIX should be coadministered with caution.  	
PLAVIX	heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	heparin	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	heparin	18	19	false	none	Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	insulin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	insulin	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	insulin	18	19	false	none	Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	cholesterol	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	cholesterol	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	cholesterol	18	19	false	none	Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
PLAVIX	omeprazole	4	2	true	negative	Concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.  Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
warfarin	digoxin	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	naproxen	11	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  NSAIDs and PLAVIX should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  	
warfarin	atenolol	11	13	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with PLAVIX should be undertaken with caution.  (See                                       PRECAUTIONS: General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
warfarin	Heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
warfarin	phenytoin	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	clopidogrel bisulfate	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	clopidogrel	17	16	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	clopidogrel	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	tolbutamide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
warfarin	insulin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
warfarin	cholesterol	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
digoxin	atenolol	15	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
digoxin	phenytoin	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
digoxin	clopidogrel bisulfate	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
digoxin	clopidogrel	15	16	true	negative	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
digoxin	clopidogrel	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
digoxin	tolbutamide	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
digoxin	estrogen	15	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
naproxen	Heparin	9	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
naproxen	Heparin	9	8	true	negative	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
naproxen	heparin	9	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
naproxen	heparin	9	8	true	negative	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of PLAVIX was associated with increased occult gastrointestinal blood loss.  	
atenolol	clopidogrel bisulfate	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
atenolol	clopidogrel	13	15	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
atenolol	estrogen	13	14	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when PLAVIX was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
aspirin	Heparin	5	7	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	Heparin	6	7	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	Heparin	6	8	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
aspirin	clopidogrel	3	1	true	negative	Drug Interactions                                                 Since clopidogrel is metabolized to its active metabolite by CYP2C19, use of drugs that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel and a reduction in clinical efficacy.  Concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.  Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
aspirin	clopidogrel	3	3	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
aspirin	clopidogrel	4	3	true	negative	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
aspirin	clopidogrel	5	3	false	none	Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
aspirin	heparin	5	7	false	none	PLAVIX potentiated the effect of aspirin on collagen-induced platelet aggregation.  PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	heparin	6	7	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	heparin	6	8	false	none	PLAVIX and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
aspirin	omeprazole	3	2	true	negative	Concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.  Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
aspirin	omeprazole	4	2	true	negative	Concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.  Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by PLAVIX.  	
Heparin	phenytoin	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Heparin	clopidogrel	19	20	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  There are no data on the concomitant use of oral anticoagulants, non study oral anti-platelet drugs and chronic NSAIDs with clopidogrel.  	
Heparin	tolbutamide	19	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Heparin	heparin	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Heparin	heparin	7	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Heparin	heparin	7	8	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
Heparin	heparin	8	7	false	none	Heparin                                                             In a study in healthy volunteers, PLAVIX did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
Heparin	heparin	8	8	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by PLAVIX.  	
Heparin	insulin	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
Heparin	cholesterol	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
phenytoin	clopidogrel bisulfate	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
phenytoin	clopidogrel	17	16	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
phenytoin	clopidogrel	17	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
phenytoin	tolbutamide	17	17	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
phenytoin	heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
phenytoin	insulin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
phenytoin	cholesterol	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	clopidogrel	15	16	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
clopidogrel bisulfate	clopidogrel	15	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
clopidogrel bisulfate	tolbutamide	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	estrogen	15	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
clopidogrel	tolbutamide	16	17	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel	tolbutamide	15	17	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel	estrogen	16	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
clopidogrel	estrogen	15	14	false	none	The pharmacodynamic activity of PLAVIX was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of PLAVIX (clopidogrel bisulfate).  	
clopidogrel	heparin	20	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  There are no data on the concomitant use of oral anticoagulants, non study oral anti-platelet drugs and chronic NSAIDs with clopidogrel.  	
clopidogrel	insulin	20	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  There are no data on the concomitant use of oral anticoagulants, non study oral anti-platelet drugs and chronic NSAIDs with clopidogrel.  	
clopidogrel	cholesterol	20	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  There are no data on the concomitant use of oral anticoagulants, non study oral anti-platelet drugs and chronic NSAIDs with clopidogrel.  	
clopidogrel	omeprazole	1	2	false	none	Drug Interactions                                                 Since clopidogrel is metabolized to its active metabolite by CYP2C19, use of drugs that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel and a reduction in clinical efficacy.  Concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.  	
clopidogrel	omeprazole	3	2	true	negative	Concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.  Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
tolbutamide	heparin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
tolbutamide	insulin	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
tolbutamide	cholesterol	17	19	false	none	Accordingly, PLAVIX may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with PLAVIX.  In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
heparin	insulin	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
heparin	cholesterol	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
insulin	cholesterol	19	19	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with PLAVIX received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), thrombolytics, heparins (unfractionated and LMWH), GPIIb/IIIa antagonists, antiepileptic agents and hormone replacement therapy without evidence of clinically significant adverse interactions.  	
|endresults
